BR112014011768A2 - forma 2 de ciclosporina a e método de produção da mesma - Google Patents

forma 2 de ciclosporina a e método de produção da mesma

Info

Publication number
BR112014011768A2
BR112014011768A2 BR112014011768A BR112014011768A BR112014011768A2 BR 112014011768 A2 BR112014011768 A2 BR 112014011768A2 BR 112014011768 A BR112014011768 A BR 112014011768A BR 112014011768 A BR112014011768 A BR 112014011768A BR 112014011768 A2 BR112014011768 A2 BR 112014011768A2
Authority
BR
Brazil
Prior art keywords
cyclosporine
production method
cyclosporin
keratoconjunctivitis
production
Prior art date
Application number
BR112014011768A
Other languages
English (en)
Portuguese (pt)
Inventor
Wu Ke
W Smith Scott
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112014011768A2 publication Critical patent/BR112014011768A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • C07K7/645Cyclosporins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • C07K1/306Extraction; Separation; Purification by precipitation by crystallization
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112014011768A 2011-11-15 2012-11-14 forma 2 de ciclosporina a e método de produção da mesma BR112014011768A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559830P 2011-11-15 2011-11-15
PCT/US2012/064985 WO2013074608A1 (en) 2011-11-15 2012-11-14 Cyclosporine a form 2 and method of making same

Publications (1)

Publication Number Publication Date
BR112014011768A2 true BR112014011768A2 (pt) 2017-05-09

Family

ID=47222337

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011768A BR112014011768A2 (pt) 2011-11-15 2012-11-14 forma 2 de ciclosporina a e método de produção da mesma

Country Status (11)

Country Link
US (4) US8796221B2 (enExample)
EP (2) EP2780358B1 (enExample)
JP (2) JP6204921B2 (enExample)
KR (1) KR102072252B1 (enExample)
CN (1) CN104039813B (enExample)
AU (3) AU2012339693B2 (enExample)
BR (1) BR112014011768A2 (enExample)
CA (1) CA2856034C (enExample)
ES (2) ES2666191T3 (enExample)
RU (1) RU2635547C2 (enExample)
WO (1) WO2013074608A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013074608A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Cyclosporine a form 2 and method of making same
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
KR20170030093A (ko) 2014-07-18 2017-03-16 알레간 인코포레이티드 결막하 및 눈주위 주사를 위한 사이클로스포린 a의 현탁액 조성물
WO2016112321A1 (en) 2015-01-08 2016-07-14 Allergan, Inc. Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
CN113117359B (zh) * 2021-03-05 2022-08-26 湘雅生物医药(湖州)有限公司 一种用于胶原蛋白提取用的无菌式蒸馏瓶
WO2024085235A1 (ja) 2022-10-20 2024-04-25 中外製薬株式会社 環状ペプチドの結晶の製造方法
TW202502802A (zh) 2023-03-20 2025-01-16 日商中外製藥股份有限公司 環狀胜肽共晶體的製造方法
CN116879437A (zh) * 2023-07-11 2023-10-13 苏州欧康维视生物科技有限公司 一种检测眼用植入剂的体外释放的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851152T2 (de) 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
HU203564B (en) * 1987-12-21 1991-08-28 Sandoz Ag Process for producing new orthorombos cyclosporin without solvatation
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
GB9105705D0 (en) * 1991-03-18 1991-05-01 Sandoz Ltd Improvements in or relating to organic compounds
US5382714A (en) * 1994-03-17 1995-01-17 The Catholic University Of America Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof
SK164796A3 (en) * 1994-11-03 1997-06-04 Dresden Arzneimittel Novel cyclosporine preparation forms for oral administration of and process for producing them
TW581681B (en) * 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
JP4208281B2 (ja) * 1998-02-26 2009-01-14 キヤノン株式会社 積層型光起電力素子
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
EP2714720B1 (en) * 2011-05-27 2018-12-26 Allergan, Inc. A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof
WO2013074608A1 (en) * 2011-11-15 2013-05-23 Allergan, Inc. Cyclosporine a form 2 and method of making same

Also Published As

Publication number Publication date
US10017541B2 (en) 2018-07-10
EP2780358A1 (en) 2014-09-24
US20140303343A1 (en) 2014-10-09
JP6204921B2 (ja) 2017-09-27
RU2635547C2 (ru) 2017-11-14
CN104039813B (zh) 2017-08-29
US20160272681A1 (en) 2016-09-22
KR20140101790A (ko) 2014-08-20
AU2017272197A1 (en) 2018-01-04
CA2856034C (en) 2017-12-12
JP2017210488A (ja) 2017-11-30
EP3067363A1 (en) 2016-09-14
HK1202124A1 (zh) 2015-09-18
JP6513755B2 (ja) 2019-05-15
CN104039813A (zh) 2014-09-10
RU2014123468A (ru) 2015-12-27
US20130123193A1 (en) 2013-05-16
KR102072252B1 (ko) 2020-01-31
EP2780358B1 (en) 2016-03-23
AU2012339693B2 (en) 2017-09-07
US9352014B2 (en) 2016-05-31
CA2856034A1 (en) 2013-05-23
AU2019204591B2 (en) 2021-03-25
WO2013074608A1 (en) 2013-05-23
US20180312543A1 (en) 2018-11-01
ES2666191T3 (es) 2018-05-03
JP2014533300A (ja) 2014-12-11
ES2578154T3 (es) 2016-07-21
EP3067363B1 (en) 2018-01-17
US8796221B2 (en) 2014-08-05
AU2019204591A1 (en) 2019-07-18
AU2012339693A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
BR112014011768A2 (pt) forma 2 de ciclosporina a e método de produção da mesma
IL260585B (en) Compositions and methods for treating retinal diseases
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
EA201492031A1 (ru) Способы лечения диабетической ретинопатии и других офтальмологических заболеваний
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
JOP20170147B1 (ar) تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة
ECSP14010817A (es) Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas
EA201490546A1 (ru) Замещенные аннелированные пиримидины и их применение
MX2015005947A (es) Formas de dosificacion de ruxolitinib de liberacion sostenida.
BR112013033841A2 (pt) extrato de levedura dermatologicamente eficaz
UA114705C2 (uk) Андрогенна композиція для лікування офтальмологічного захворювання
EP2784152A4 (en) METHOD FOR PRODUCING NETWORK SKIN TISSUE AND RETINO-TREATED CELLS
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
CL2013002467A1 (es) Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.
BR112016012129A8 (pt) métodos para produção, expansão e purificação de células epiteliais do pigmento da retina, composição farmacêutica e uso das células
EP2279247A4 (en) STEM CELLS OF THE RETINAL PIGMENTARY EPITHELIUM
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
MX2024010721A (es) Formulaciones topicas que contienen ciclosporina y usos de las mismas.
EA201690798A1 (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
EA201490012A1 (ru) Опсин-связывающие лиганды, композиции и способы их использования
EA201690532A1 (ru) Не содержащий консерванта офтальмологический фармацевтический состав
BR112016008786A2 (pt) siRNA E SEUS USOS EM MÉTODOS E COMPOSIÇÕES PARA INIBIÇÃO DE EXPRESSÃO DO GENE ORAI1
BR112014011733A2 (pt) suspensões autoclaváveis da forma 2 de ciclosporina a
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.